Skip to main content
. 2019 Jan 7;69(9):1613–1620. doi: 10.1093/cid/ciz008

Figure 1.

Figure 1.

Ten-year risk of all-cause mortality under direct-acting antiviral treatment criteria among people with human immunodeficiency virus (HIV) and hepatitis C virus in the Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994–2015. A, Treat none at baseline (solid line) vs treat all at baseline (dotted line). B, Treat once HIV virally suppressed (solid line) vs treat same percentage of people at random at baseline (dotted line). C, Treat once progressed to severe fibrosis or cirrhosis (solid line) vs treat same percentage of people at random at baseline (dotted line). D, Treat once HIV virally suppressed and progressed to severe fibrosis or cirrhosis (solid line) vs treat same percentage of people at random at baseline (dotted line). Note that in all 4 panels, a lower curve indicates lower mortality, and thus in panels (B–D), treating people at random at baseline is generally superior to treating based on the stated criteria.